자기공명영상(MRI) 시장 : 제품 유형별, 자장 강도별, 자석 유형별, 코일 유형별, 용도별, 최종 사용자별 - 시장 예측(2026-2032년)

The Magnetic Resonance Imaging Market was valued at USD 6.48 billion in 2025 and is projected to grow to USD 6.83 billion in 2026, with a CAGR of 5.91%, reaching USD 9.69 billion by 2032.

An authoritative introduction framing MRI as a convergent clinical technology and service paradigm that shapes procurement, workflows, and patient-centric care

Magnetic resonance imaging continues to stand at the intersection of clinical innovation and healthcare systems transformation, delivering unparalleled diagnostic clarity while adapting to evolving operational constraints. This introduction frames MRI as both a technology platform and a service paradigm, where advances in hardware, software, and care models converge to influence procurement, utilization, and patient pathways.

Over recent years, image quality improvements have been accompanied by growing expectations for throughput, accessibility, and cost-effectiveness. Consequently, stakeholders across the imaging ecosystem are recalibrating priorities: vendors are balancing R&D investments between high-field performance and low-cost accessibility, while providers are integrating MRI into multidisciplinary care protocols and value-based delivery models. Transitioning from episodic capital acquisition to lifecycle-oriented service agreements and outcome-focused delivery has become a critical strategic consideration.

Moving forward, MRI's strategic value will be judged by its ability to deliver diagnostic confidence, interoperability within diagnostic chains, and demonstrable contributions to patient outcomes. This introduction sets the stage for an in-depth examination of technological shifts, policy impacts, segmentation-driven dynamics, regional variations, competitive positioning, and practical recommendations that follow.

How converging magnet technologies, AI-driven imaging advances, evolving service models, and regulatory expectations are reshaping MRI clinical and commercial pathways

The MRI landscape is undergoing transformative shifts driven by simultaneous advances in magnet design, image reconstruction algorithms, and clinical workflow integration. High-performance scanners and evolving low-field architectures are reshaping the trade-offs between image resolution, cost, and accessibility. At the same time, AI-enabled reconstruction and automation are accelerating scan times, reducing dependence on highly specialized operators, and enabling new protocols that expand clinical utility across patient cohorts.

In parallel, the aftermarket and service models are evolving: service contracts increasingly emphasize uptime guarantees, predictive maintenance, and remote diagnostics to protect clinical continuity. Supply-chain diversification and modular hardware architectures are reducing lead times and enabling incremental upgrades rather than full replacements. These developments are prompting providers to adopt mixed-portfolio strategies, combining flagship systems for complex diagnostics with more agile platforms for routine imaging.

Regulatory frameworks and payer expectations are also shifting, with a growing emphasis on evidence of clinical effectiveness and cost utility. Consequently, stakeholders must integrate clinical validation, interoperability, and value demonstration into their commercialization and deployment strategies. Taken together, these shifts are redefining how MRI is procured, deployed, and monetized across healthcare systems.

Evaluating how 2025 tariff measures have reshaped MRI procurement, supplier strategies, and clinical access through supply-chain reconfiguration and acquisition model shifts

The policy environment introduced in 2025 has imparted material effects on MRI supply chains, procurement strategies, and cost structures across healthcare delivery systems. Tariff adjustments on imported components and finished systems have altered relative supplier competitiveness, prompting procurement teams to reevaluate total cost of ownership and to stress-test vendor supply commitments. As a result, sourcing strategies have shifted toward a combination of nearshoring, multi-vendor agreements, and strategic inventory buffering to mitigate delivery uncertainty.

These changes have consequences beyond procurement. Capital approval cycles now incorporate scenario planning for tariff-induced price volatility and potential delays in equipment deployment. Hospital finance teams and imaging centers are increasingly favoring flexible acquisition models-such as modular upgrades and service-based arrangements-that decouple clinical capacity expansion from large upfront expenditures. Simultaneously, some vendors are accelerating localization of manufacturing and establishing regional parts depots to safeguard service continuity.

Clinically, the cumulative impact has encouraged providers to optimize utilization through scheduling efficiencies and protocol standardization, thereby preserving diagnostic access amid equipment constraints. In summary, the 2025 tariff environment has accelerated structural changes in how MRI systems are sourced, serviced, and integrated into clinical delivery models.

Comprehensive segmentation insights that connect product, field strength, magnet and coil configurations, applications, and end-user dynamics to technology adoption drivers

Segmentation provides the analytical lens for understanding technology selection, clinical workflows, and purchasing behavior across the MRI ecosystem. Based on Product Type, purchasing decisions differentiate between Closed MRI systems, favored for high-field performance and broad clinical applicability, and Open MRI systems, which prioritize patient experience and certain interventional or claustrophobic patient cohorts. These product distinctions influence capital allocation, site planning, and protocol development.

Based on Field Strength, clinical programs stratify needs among High Field systems that support advanced neuro and oncologic protocols, Low Field systems that balance affordability with improved accessibility, and Ultra-High Field systems that enable cutting-edge research and specialized diagnostics. Choices in field strength intersect closely with magnet architecture. Based on Magnet Type, Permanent magnets are valued for low operating overhead in constrained settings, Resistive magnets offer specific niche advantages, and Superconducting magnets continue to dominate high-resolution clinical imaging and research environments.

Based on Coil Type, clinical utility is further refined by the availability of Body Coil, Cardiac Coil, Extremity Coil, and Head Coil options, which determine protocol specificity and multi-organ versatility. Based on Application, MRI service design must accommodate Cardiovascular, Musculoskeletal, Neurology - including Brain Imaging and Spinal Cord Imaging - and Oncology - including Hematological Cancer Imaging and Solid Tumor Imaging - each with distinct imaging requirements and throughput considerations. Finally, based on End User, deployment decisions reflect the needs of Academic And Research Institutes, Diagnostic Imaging Centers, and Hospitals, with hospital segment dynamics differentiating Private Hospitals and Public Hospitals in procurement priorities, funding models, and adoption timelines. Together, these segmentation dimensions illuminate where investment, training, and product innovation will deliver the greatest clinical and commercial return.

Regional MRI insights that delineate how infrastructure, reimbursement, and provider archetypes in each global region shape adoption trajectories and commercial strategies

Regional context drives adoption patterns, reimbursement structures, regulatory pathways, and infrastructure readiness for MRI deployment. In the Americas, capital markets, payer structures, and a dense network of private providers often accelerate adoption of higher-field systems and bundled service models, while also supporting vigorous aftermarket ecosystems. These dynamics emphasize the importance of robust service networks and value demonstration to justify premium equipment.

Across Europe, Middle East & Africa, heterogeneity in regulatory regimes and healthcare financing shapes divergent adoption curves. In many markets, constrained capital allocation and centralized procurement encourage the adoption of cost-effective platforms and shared-service models, whereas leading academic centers continue to invest in ultra-high-field systems tied to research excellence. Infrastructure variability also increases the importance of modular and low-maintenance designs in several regions within this cluster.

The Asia-Pacific region exhibits rapid expansion in diagnostic capacity driven by growing investment in healthcare infrastructure, demographic trends, and policy initiatives to broaden access. This environment favors scalable solutions that combine affordability with upgrade pathways and strong local service models. Taken together, regional distinctions require tailored commercial strategies that align product positioning with reimbursement realities, local clinical priorities, and supply-chain ecosystems.

Key company-level insights showcasing how product differentiation, aftermarket excellence, strategic partnerships, and flexible commercial models create sustainable competitive advantage

Leading participants within the MRI ecosystem are differentiating through a combination of technological innovation, aftermarket excellence, and strategic partnerships. Some vendors concentrate R&D on algorithmic image enhancement and workflow automation to improve throughput and lower per-study costs, while others prioritize hardware differentiation through magnet and coil innovations that expand clinical capability. These divergent approaches underscore the importance of aligning product investments with identified clinical unmet needs and end-user preferences.

Service and support capabilities have emerged as competitive differentiators. Organizations that offer predictive maintenance, rapid parts provisioning, and outcome-oriented service agreements strengthen customer retention and reduce operational risk for providers. Meanwhile, alliances between vendors, software providers, and clinical networks create ecosystems that streamline deployment of new protocols and facilitate multicenter evidence generation. Investment in training and clinical support further reinforces adoption by reducing the time to clinical utility.

Finally, growth strategies increasingly rely on flexible commercial models-rental, pay-per-scan, or managed equipment services-that lower barriers to entry for constrained facilities and enable incremental scaling. Companies that integrate clinical evidence generation, robust service models, and adaptable commercial terms will be best positioned to capture long-term preference in a competitive landscape.

Actionable strategic recommendations for OEMs, providers, and distributors to strengthen product roadmaps, service models, supply chains, and payer engagement for sustained growth

Industry leaders should prioritize a set of strategic actions to navigate technological, regulatory, and market pressures while maximizing clinical impact and commercial resilience. First, invest in platform modularity and upgrade pathways that reduce replacement cycles and enable customers to scale functionality incrementally. Such an approach lowers customer acquisition friction and aligns vendor incentives with long-term clinical value delivery.

Second, expand service propositions beyond traditional maintenance to include predictive analytics, outcome-linked service level agreements, and clinician training programs. These elements not only protect uptime but also embed vendors more deeply into clinical pathways, creating stickiness and defensibility. Third, pursue supply-chain diversification and regional manufacturing or components localization where feasible to reduce exposure to policy-driven cost shocks and to shorten lead times for parts and systems.

Fourth, collaborate with payers and health systems to develop evidence packages that demonstrate diagnostic and care-pathway value, thereby supporting coverage and utilization. Finally, tailor commercial models-such as subscription, managed services, and shared ownership-to align with varied end-user financial constraints. Implementing these recommendations will enable vendors and providers to deliver measurable clinical benefits while buffering against market volatility.

A transparent mixed-methods research methodology integrating expert engagement, secondary evidence synthesis, and analytical frameworks to validate MRI market insights

This study synthesizes insights from a mixed-methods research approach designed to ensure transparency, reproducibility, and relevance to decision-makers. The methodology integrates structured engagements with clinical and commercial experts, secondary analysis of regulatory and policy documents, and systematic review of technology literature to contextualize technological trajectories and adoption patterns. These elements are triangulated to validate findings and to reduce bias.

Primary research involved interviews and workshops with stakeholders across clinical specialties, procurement offices, and senior vendor leadership to capture real-world decision criteria, pain points, and early indicators of technology adoption. Secondary research sources comprised peer-reviewed clinical studies, regulatory filings, and supplier product documentation to corroborate claims related to performance, safety, and intended use. Analytical frameworks applied include lifecycle cost analysis for procurement considerations, clinical pathway mapping to assess service impact, and scenario analysis to evaluate policy and supply-chain contingencies.

Quality assurance measures included cross-verification of interview inputs, internal peer review of analytical outputs, and sensitivity checks on key interpretive conclusions. This methodological rigor underpins the report's actionable conclusions and recommendations for stakeholders seeking to align strategy with evolving MRI ecosystem dynamics.

Conclusive synthesis aligning technological advances, policy impacts, segmentation realities, and regional differences to guide strategic MRI investments and program design

This concluding synthesis reconciles technology trends, policy shifts, segmentation dynamics, and regional contexts to provide a cohesive perspective on MRI's near-term trajectory. Technological advances-particularly in image reconstruction, modular hardware, and coil innovation-are expanding clinical applications while lowering some barriers to access. Concurrently, policy actions and supply-chain reconfiguration have accelerated the adoption of flexible acquisition and service models that de-risk capital investment for providers.

Segmentation analysis clarifies that clinical and commercial choices will continue to vary by field strength, magnet design, coil complement, and end-user funding models, which necessitates tailored value propositions. Regionally, diverse reimbursement and infrastructure realities demand market-entry strategies that are localized and evidence-driven. Competitive differentiation will increasingly hinge on service excellence, interoperability, and demonstrable contributions to clinical pathways.

In sum, successful stakeholders will be those who integrate technical innovation with robust service models, adaptable commercial terms, and proactive engagement with payers and providers. This integrated approach will enable MRI to retain its central role in diagnostic care while evolving to meet changing system-level imperatives.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Magnetic Resonance Imaging Market, by Product Type

• 8.1. Closed MRI
• 8.2. Open MRI

9. Magnetic Resonance Imaging Market, by Field Strength

• 9.1. High Field
• 9.2. Low Field
• 9.3. Ultra-High Field

10. Magnetic Resonance Imaging Market, by Magnet Type

• 10.1. Permanent
• 10.2. Resistive
• 10.3. Superconducting

11. Magnetic Resonance Imaging Market, by Coil Type

• 11.1. Body Coil
• 11.2. Cardiac Coil
• 11.3. Extremity Coil
• 11.4. Head Coil

12. Magnetic Resonance Imaging Market, by Application

• 12.1. Cardiovascular
• 12.2. Musculoskeletal
• 12.3. Neurology
  • 12.3.1. Brain Imaging
  • 12.3.2. Spinal Cord Imaging
• 12.4. Oncology
  • 12.4.1. Hematological Cancer Imaging
  • 12.4.2. Solid Tumor Imaging

13. Magnetic Resonance Imaging Market, by End User

• 13.1. Academic And Research Institutes
• 13.2. Diagnostic Imaging Centers
• 13.3. Hospitals
  • 13.3.1. Private Hospitals
  • 13.3.2. Public Hospitals

14. Magnetic Resonance Imaging Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Magnetic Resonance Imaging Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Magnetic Resonance Imaging Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Magnetic Resonance Imaging Market

18. China Magnetic Resonance Imaging Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. Agilent Technologies, Inc.
• 19.6. Analogic Corporation
• 19.7. Aspect Imaging Ltd.
• 19.8. Aurora Imaging Technology, Inc.
• 19.9. Bruker Corporation
• 19.10. Canon Medical Systems Corporation
• 19.11. Esaote S.p.A.
• 19.12. Fonar Corporation
• 19.13. Fujifilm Holdings Corporation
• 19.14. GE HealthCare Technologies, Inc.
• 19.15. Hitachi, Ltd.
• 19.16. Hologic, Inc.
• 19.17. IMRIS / Deerfield Imaging, Inc.
• 19.18. Koninklijke Philips N.V.
• 19.19. MR Solutions Group Ltd.
• 19.20. Neusoft Medical Systems Co., Ltd.
• 19.21. Shimadzu Corporation
• 19.22. Siemens Healthineers AG
• 19.23. Time Medical Limited
• 19.24. United Imaging Healthcare Co., Ltd.